- Home
- ENTA vs GRAF Comparison
ENTA vs GRAF Comparison
Compare ENTA & GRAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- GRAF
- Stock Information
- Founded
- ENTA 1995
- GRAF 2021
- Country
- ENTA United States
- GRAF United States
- Employees
- ENTA N/A
- GRAF N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- GRAF
- Sector
- ENTA Health Care
- GRAF
- Exchange
- ENTA Nasdaq
- GRAF NYSE
- Market Cap
- ENTA 245.4M
- GRAF 288.1M
- IPO Year
- ENTA 2013
- GRAF 2024
- Fundamental
- Price
- ENTA $9.31
- GRAF $10.02
- Analyst Decision
- ENTA Buy
- GRAF
- Analyst Count
- ENTA 3
- GRAF 0
- Target Price
- ENTA $19.67
- GRAF N/A
- AVG Volume (30 Days)
- ENTA 114.1K
- GRAF 24.9K
- Earning Date
- ENTA 11-25-2024
- GRAF 01-01-0001
- Dividend Yield
- ENTA N/A
- GRAF N/A
- EPS Growth
- ENTA N/A
- GRAF N/A
- EPS
- ENTA N/A
- GRAF 0.25
- Revenue
- ENTA $71,960,000.00
- GRAF N/A
- Revenue This Year
- ENTA N/A
- GRAF N/A
- Revenue Next Year
- ENTA $5.14
- GRAF N/A
- P/E Ratio
- ENTA N/A
- GRAF $40.39
- Revenue Growth
- ENTA N/A
- GRAF N/A
- 52 Week Low
- ENTA $8.51
- GRAF $9.03
- 52 Week High
- ENTA $17.80
- GRAF $11.02
- Technical
- Relative Strength Index (RSI)
- ENTA 28.86
- GRAF N/A
- Support Level
- ENTA $10.84
- GRAF N/A
- Resistance Level
- ENTA $10.89
- GRAF N/A
- Average True Range (ATR)
- ENTA 0.49
- GRAF 0.00
- MACD
- ENTA -0.19
- GRAF 0.00
- Stochastic Oscillator
- ENTA 18.18
- GRAF 0.00
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About GRAF GRAF GLOBAL CORP
Graf Global Corp is a blank check company.